MetaCap

Kamada (KMDA) vs Neurogene (NGNE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kamada (KMDA) has outperformed Neurogene (NGNE) over the past year, gaining 14.7% versus a gain of 10.4%. Over five years, KMDA leads with a +22.7% price change compared with -78.3% for NGNE. Neurogene is the larger company by market cap ($458.5 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs -100.0%).

Kamada pays a dividend yielding 7.24%, while Neurogene does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KMDA+14.67%NGNE+10.42%
+120%+48%-25%
Nov 21, 20251 yearNov 20, 2026
KMDA+38.21%NGNE-79.10%
+66%-17%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KMDA versus NGNE key metrics
MetricKMDANGNE
Share price$7.74$22.15
Market cap$446.85M$458.53M
1-day change-1.15%-3.40%
YTD return+9.63%+7.52%
1-year return+14.67%+10.42%
5-year return+22.66%-78.33%
P/E ratio (TTM)20.37—
Forward P/E13.34—
EPS (TTM)$0.38$-5.03
Dividend yield7.24%0.00%
Annual dividend$0.56$0.00
Revenue (latest FY)$180.46M$0
Revenue growth (YoY)+12.12%-100.00%
Net income (latest FY)$20.20M$-90.35M
Gross margin42.34%—
Operating margin14.54%—
Net margin11.19%—
52-week high$9.35$43.66
52-week low$6.63$15.93
Distance from 52-week high-17.22%-49.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.65%+250.47%
Average volume121.87K307.78K
Shares outstanding57.73M20.70M
Employees462131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada grew revenue faster in its latest fiscal year (+12.12% vs -100.00%).

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

About Neurogene

NGNE stock →

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

KMDA vs NGNE FAQ

Which is bigger, Kamada or Neurogene?

Neurogene (NGNE) is larger, with a market capitalization of $458.53M compared with $446.85M for Kamada (KMDA).

Which stock has performed better over the past year, KMDA or NGNE?

KMDA returned +14.67% over the past 12 months, compared with +10.42% for NGNE (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Kamada or Neurogene?

Kamada pays a dividend yielding 7.24%, while Neurogene does not currently pay a regular dividend.

Are Kamada and Neurogene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons